Peringatan Keamanan

Symptoms of overdose include nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma. Possible symptoms, seen after overdosage with other pyrazolone derivatives: anemia, jaundice, and ulceration.

Sulfinpyrazone

DB01138

small molecule approved

Deskripsi

A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

Struktur Molekul 2D

Berat 404.482
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 4-6 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food.

Interaksi Obat

831 Data
Apixaban The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Sulfinpyrazone.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Sulfinpyrazone.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulfinpyrazone.
Obinutuzumab The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Sulfinpyrazone.
Rivaroxaban Sulfinpyrazone may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Sulfinpyrazone.
Urokinase Sulfinpyrazone may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Sulfinpyrazone.
Troglitazone Troglitazone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Erythromycin The serum concentration of Sulfinpyrazone can be increased when it is combined with Erythromycin.
Reserpine Reserpine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Progesterone Progesterone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Chlorpromazine Chlorpromazine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Bosentan Bosentan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Glyburide Glyburide may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Fusidic acid Fusidic acid may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Valinomycin Valinomycin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Nifedipine Nifedipine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Olmesartan Olmesartan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.
Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Sulfinpyrazone.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Sulfinpyrazone.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Sulfinpyrazone.
Perampanel The metabolism of Perampanel can be increased when combined with Sulfinpyrazone.
Warfarin The metabolism of Warfarin can be increased when combined with Sulfinpyrazone.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Sulfinpyrazone.
(R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Sulfinpyrazone.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Sulfinpyrazone.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Sulfinpyrazone.
(S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Sulfinpyrazone.
Nitrofurantoin The serum concentration of Nitrofurantoin can be increased when it is combined with Sulfinpyrazone.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Sulfinpyrazone.
Pegloticase The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Pegloticase.
Limaprost Limaprost may increase the antiplatelet activities of Sulfinpyrazone.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Sulfinpyrazone.
Tositumomab The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tositumomab.
Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Sulfinpyrazone.
Lepirudin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fondaparinux.
Phenprocoumon The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Epoprostenol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Prasugrel.
Sulodexide The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Astaxanthin.
Otamixaban The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Amediplase.
Danaparoid The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tinzaparin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ditazole.

Target Protein

Solute carrier family 22 member 12 SLC22A12
Multidrug resistance-associated protein 1 ABCC1
ATP-binding cassette sub-family C member 2 ABCC2
Nuclear receptor subfamily 1 group I member 2 NR1I2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 4616423
    Didisheim P, Kazmier FJ, Fuster V: Platelet inhibition in the management of thrombosis. Thromb Diath Haemorrh. 1974 Sep 30;32(1):21-34.
  • PMID: 7000488
    Margulies EH, White AM, Sherry S: Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. Drugs. 1980 Sep;20(3):179-97.
  • PMID: 2407421
    Schrader BJ, Berk SI: Antiplatelet agents in coronary artery disease. Clin Pharm. 1990 Feb;9(2):118-24.
  • PMID: 14592561
    van Gijn J, Algra A: Aspirin and stroke prevention. Thromb Res. 2003 Jun 15;110(5-6):349-53.

Contoh Produk & Brand

Produk: 16 • International brands: 0
Produk
  • Antazone Tab 100mg
    Tablet • 100 mg • Oral • Canada • Approved
  • Antazone Tab 200mg
    Tablet • 200 mg • Oral • Canada • Approved
  • Anturan 100mg
    Tablet • 100 mg / tab • Oral • Canada • Approved
  • Anturan 200mg
    Tablet • 200 mg / tab • Oral • Canada • Approved
  • Anturane
    Tablet • 100 mg/1 • Oral • US • Approved
  • Anturane
    Capsule • 200 mg/1 • Oral • US • Approved
  • Apo Sulfinpyrazone Tab 100mg
    Tablet • 100 mg • Oral • Canada • Generic • Approved
  • Novo-pyrazone Tab 100mg
    Tablet • 100 mg • Oral • Canada • Generic • Approved
Menampilkan 8 dari 16 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul